Novaliq is transforming ocular therapeutics
Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. EyeSol® is designed to unfold the full potential of eye care treatments.
EyeSol® enhances corneal residence time and ocular coverage, providing better bioavailability and faster onset. EyeSol® products are water-free and therefore obviate preservatives.
With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye diseases.
NOV03 and CyclASol® 0.1% provide novelties in the treatment of DED allowing a pathogenesis-driven treatment building on the unique properties of EyeSol®. The two investigational drugs have been designed to distinctly target either predominantly aqueous or evaporative dry eye disease as this is critical for therapeutic success. Both are currently in phase 3 development:
- NOV03 (100% perfluorohexyloctane) is the first drug developed to treat signs and symptoms of evaporative DED associated with Meibomian gland dysfunction in a highly effective way.
- CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of signs and symptoms of aqueous deficient DED showing sustained efficacy on ocular surface healing.
Both investigational drugs have demonstrated superior clinical benefits, with an early onset of action and an excellent tolerability profile. Novaliq expects to conclude both clinical developments in 2020.
Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA.
The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.